IP Market Intelligence

Patent Renewals Aren't Boring — They're a €100K Pipeline Hiding in Plain Sight

September 28, 2026 · 6 min read · LeadLex Editorial

There is a category of IP work that almost every firm treats as administrative: renewals. Patent annuities, trademark renewals, registered design renewals, design patent renewals. Recurring, deadline-driven, low-margin per matter. Often outsourced to annuity providers. Mostly invisible to BD.

This is a mistake. Renewals are not administrative. Renewals are decision points. Every renewal cycle is a moment when the corporate is, briefly and quietly, evaluating whether their current arrangement is the right one.

Most IP firms walk past this signal because they were trained to walk past it. The firms that don't — that treat the renewal cycle as a BD pipeline — quietly take share from competitors who treat it as paperwork.

TL;DR

Patent and trademark renewals are deadline-driven decision points. Corporates either continue with the incumbent provider or evaluate alternatives.
The economics make this matter. A medium-sized corporate IP portfolio renewing across multiple jurisdictions can represent €50K–€500K+ of annual fee revenue, plus the portfolio-strategy work that often accompanies renewal reviews.
The strategic conversation that matters more: which assets to renew, which to abandon, and where to expand. That conversation is the entry point to higher-margin advisory work — the renewal itself is the wedge.
Most firms don't track renewal cycles as BD signals because the data isn't surfaced continuously and the partner who should act doesn't know the cycle is coming.
The firms that do — and that approach renewal moments with substantive portfolio-strategy intelligence, not just "we can do your renewals cheaper" — capture meaningful share from the annuity-provider commodity layer.

Why renewals are misunderstood

The IP renewal industry is dominated by annuity providers — companies that exist to process renewals at scale, at low cost, with high reliability. CPA Global (now Clarivate), Dennemeyer, Murgitroyd, Marks & Clerk's renewal arm, and others. They are good at what they do.

That structure has trained the IP profession to think of renewals as commoditized work, beneath the dignity of senior counsel attention. In some ways that's correct — the mechanical act of paying an annuity is genuinely low-margin and best handled at scale.

But the renewal decision is not commoditized. The decision of which marks to renew, which patents to maintain in which jurisdictions, which to abandon, and where to expand is strategic. It is the kind of question a senior partner should be having with the Head of IP — and it is usually being asked once a year, at the renewal cycle.

The firms that show up with substantive thinking at that moment capture the portfolio-strategy conversation. The strategy conversation is where the high-margin work originates.

The economics

A medium-sized corporate trademark portfolio: 500 marks across 30 jurisdictions, with roughly 10–15% renewing each year. Annual renewal fees might be €40K–€80K, plus the costs of evaluating new filings, defending oppositions, and managing the portfolio.

A medium-sized corporate patent portfolio: 200 patent families with 1,000+ national stages active, roughly 15–25% of the cost base concentrated in renewal years 6, 10, 15, and 20. Annual renewal costs commonly run €100K–€400K, with significant strategic decisions about which national stages to maintain.

For the IP firm, this is not the work itself — the actual annuity payments are usually outsourced. The work is the strategy around renewal. Which patents are worth maintaining? Which classes are over-protected? Where is the portfolio thinly stretched? Where is it geographically misaligned with the business?

A serious portfolio-strategy review for a mid-sized corporate is 40–120 hours of senior counsel time. At €600 per hour, that's €24K–€72K per review. Done annually, that's a six-figure recurring revenue line plus the related new-filing work that comes out of the review.

That is the pipeline most firms don't see because they treat renewals as paperwork.

The signals to track

For renewals to function as BD pipeline, the firm needs to know:

Which portfolios in the firm's prospect universe are entering significant renewal cycles in the next 12–18 months? Patent portfolios at year 9–10 transitions, year 14–15 transitions, and year 19–20 transitions are particularly material. Trademark portfolios at 10-year renewal cycles compound across the calendar.
Which portfolios are currently being managed by an annuity provider rather than a strategic IP firm? Annuity-provider relationships are commodity relationships. They renew on price and reliability. They are easier to displace than long-term strategic relationships.
Which corporates have recently appointed a new Head of IP whose first move will be a portfolio audit? Renewal cycles overlap with panel reviews in a particularly opportune way.
Which corporates have publicly indicated portfolio-rationalization initiatives? Cost-cutting language in annual reports, layoff announcements affecting the IP function, M&A activity that's about to put portfolio decisions in front of new owners.
Which technologies or product lines are facing strategic decisions (sunset, spin-off, divestiture) that will drive renewal-period choices?

Most of this data is public. Patent renewal cycles are calendar-able from grant dates. Trademark renewal cycles are calendar-able from registration dates. Annuity-provider engagements are often discoverable from filing records. The audit-after-new-Head-of-IP signal overlaps directly with the in-house counsel moves signal.

The combination — calendar data plus signal data — is what produces a tractable BD list.

The conversation that converts

The wrong way to approach a renewal cycle: "We noticed your portfolio is entering renewals next year and we can offer a more competitive rate."

This conversation has been had with the corporate before. The annuity provider is already cheaper than any IP firm. The price conversation is unwinnable.

The right way: "We noticed your portfolio is entering a significant renewal cycle next year. Several portfolios in your sector are using this moment to rebalance — divesting older national stages, focusing the design coverage on top markets, and reallocating budget toward newer technology areas. Happy to send a short note on what we're seeing if useful."

That conversation is portfolio strategy. It is what a Head of IP wants to be talking about. It is not what an annuity provider can offer.

The right partner for this conversation is a senior IP partner with strategic credibility, not a BD director or junior associate. The conversation typically starts as an intelligence offer, develops into a scoped strategy review, and matures into ongoing portfolio management work.

The annuity-provider problem in reverse

A note for firms that already have IP clients on their roster: your incumbency does not protect you here. If you're managing a corporate's portfolio but treating renewals as routine, a competitor firm will arrive at the next major renewal cycle with portfolio-strategy thinking and you will be the firm whose renewal "got reviewed" with you not in the room.

The defensive version of this playbook is also the offensive version. Show up to your existing clients' renewal cycles with substantive strategy thinking. Audit which jurisdictions are over-protected. Recommend which assets to abandon. Surface where the portfolio is misaligned with the business. Be the strategic firm, not the annuity firm.

Firms that operate this way retain accounts longer and grow share within them. Firms that don't lose share at exactly the renewal moments they should be deepening.

What an AI BD system does with renewal signals

The mechanical part: ingest grant data and registration data from the major patent and trademark offices; project renewal cycles forward; cross-reference against the firm's existing client portfolios and prospect list; surface renewal cycles with material BD potential 12–18 months in advance, with the data needed for a substantive outreach.

The judgment part: the partner decides which portfolios to approach strategically, what the substantive intelligence is, and how to position the conversation. The AI does the data work. The partner does the strategy work.

Reporting and metrics

The metrics that tell you whether your firm is operating renewals as a BD channel:

Renewal cycles surfaced 12+ months in advance as a percentage of total addressable cycles in the firm's prospect universe
Substantive outreach (not generic) on renewal triggers — count and quality
Portfolio-strategy reviews scoped or sold per quarter traceable to renewal-cycle outreach
Annual recurring revenue tied to renewal-anchored relationships

If you cannot pull those numbers, you are not operating renewals as BD. The work is happening; the leverage is not.

FAQs

Aren't renewals just handled by annuity providers?

The payment of renewals is handled by annuity providers, efficiently and at scale. The decisions around renewals — what to maintain, what to abandon, where to expand — are strategy decisions that benefit from senior counsel input. The strategic conversation is the BD opportunity; the mechanical work usually stays with the annuity provider.

Can a firm displace an annuity provider?

For pure annuity work — payment and routine maintenance — usually not, and trying to compete on price is a losing strategy. The play is to win the strategic portfolio work that sits above the annuity layer, while leaving the mechanical processing where it is.

How far in advance should we approach a renewal-cycle prospect?

For trademark renewals, 6–12 months. For significant patent renewal transitions (year 9–10, 14–15, 19–20), 12–18 months. Strategic conversations of this kind need time to develop; they don't close in 60 days.

Is this approach equally valuable for trademark and patent practice?

Yes, with different rhythms. Trademark renewals come every 10 years and are predictable; the BD opportunity is in the portfolio-strategy review that often accompanies them. Patent renewals come more frequently with rising annuity fees over time; the BD opportunity is concentrated around the cost-decision moments (years 9–10 and 14–15 are particularly material in many jurisdictions).

What if our firm doesn't have the strategic depth to deliver the portfolio-strategy work?

Then renewals are not currently a BD channel for you. Build the depth (or acquire it via lateral hires) before pursuing the strategy conversation; otherwise the conversation goes badly when the corporate engages substantively.